Login to Your Account

$450M in Potential Milestones

Fibrogen Oral Anemia Therapy Gets $350M from Astrazeneca

By Randy Osborne
Staff Writer

Thursday, August 1, 2013
Pipeline-scanty Astrazeneca plc wagered big on Fibrogen Inc.'s late-stage FG-4592, the oral prolyl hydroxylase inhibitor for anemia, forking over $350 million up front and another potential $450 million in milestone payments.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription